全文获取类型
收费全文 | 176777篇 |
免费 | 13594篇 |
国内免费 | 4257篇 |
专业分类
耳鼻咽喉 | 2110篇 |
儿科学 | 9201篇 |
妇产科学 | 4620篇 |
基础医学 | 20347篇 |
口腔科学 | 2377篇 |
临床医学 | 17258篇 |
内科学 | 30140篇 |
皮肤病学 | 3268篇 |
神经病学 | 24440篇 |
特种医学 | 3989篇 |
外国民族医学 | 13篇 |
外科学 | 15860篇 |
综合类 | 20165篇 |
现状与发展 | 17篇 |
一般理论 | 4篇 |
预防医学 | 10124篇 |
眼科学 | 3111篇 |
药学 | 10934篇 |
64篇 | |
中国医学 | 12831篇 |
肿瘤学 | 3755篇 |
出版年
2024年 | 325篇 |
2023年 | 3135篇 |
2022年 | 4704篇 |
2021年 | 8855篇 |
2020年 | 7984篇 |
2019年 | 7566篇 |
2018年 | 7411篇 |
2017年 | 7022篇 |
2016年 | 6513篇 |
2015年 | 6289篇 |
2014年 | 12592篇 |
2013年 | 14187篇 |
2012年 | 10250篇 |
2011年 | 11397篇 |
2010年 | 8755篇 |
2009年 | 8382篇 |
2008年 | 8063篇 |
2007年 | 7686篇 |
2006年 | 6793篇 |
2005年 | 5596篇 |
2004年 | 5001篇 |
2003年 | 4392篇 |
2002年 | 3089篇 |
2001年 | 2738篇 |
2000年 | 2453篇 |
1999年 | 2187篇 |
1998年 | 1837篇 |
1997年 | 1772篇 |
1996年 | 1572篇 |
1995年 | 1446篇 |
1994年 | 1257篇 |
1993年 | 1136篇 |
1992年 | 987篇 |
1991年 | 797篇 |
1990年 | 725篇 |
1989年 | 609篇 |
1988年 | 586篇 |
1987年 | 526篇 |
1986年 | 448篇 |
1985年 | 1107篇 |
1984年 | 1099篇 |
1983年 | 720篇 |
1982年 | 865篇 |
1981年 | 755篇 |
1980年 | 618篇 |
1979年 | 562篇 |
1978年 | 429篇 |
1977年 | 331篇 |
1976年 | 296篇 |
1975年 | 270篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
15.
16.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
17.
18.
《Vaccine》2022,40(16):2370-2378
Porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (M. hyopneumoniae, Mhp) are two of the most common pathogens involved in the porcine respiratory disease complex (PRDC) resulting in significant economic losses worldwide. Vaccination is the most effective approach to disease prevention. Since PRRSV and Mhp co-infections are very common, an efficient dual vaccine against these pathogens is required for the global swine industry. Compared with traditional vaccines, multi-epitope vaccines have several advantages, they are comparatively easy to produce and construct, are chemically stable, and do not have an infectious potential. In this study, to develop a safe and effective vaccine, B cell and T cell epitopes of PRRSV-GP5, PRRSV-M, Mhp-P46, and Mhp-P65 protein had been screened to construct a recombinant epitope protein rEP-PM that has good hydrophilicity, strong antigenicity, and high surface accessibility, and each epitope is independent and complete. After immunization in mice, rEP-PM could induce the production of high levels of antibodies, and it had good immunoreactivity with anti-rEP-PM, anti-PRRSV, and anti-Mhp antibodies. The anti-rEP-PM antibody specifically recognizes proteins from PRRSV and Mhp. Moreover, rEP-PM induced a Th1-dominant cellular immune response in mice. Our results showed that the rEP-PM protein could be a potential candidate for the development of a safe and effective multi-epitope peptide combined vaccine to control PRRSV and Mhp infections. 相似文献
19.
多囊卵巢综合征(polycystic ovary syndrome,PCOS)是一种内分泌代谢紊乱综合征,临床表现高度异质性。肥胖是PCOS异质性临床表现之一,超过50%的PCOS患者超重或肥胖。肥胖型PCOS主要表现为高雄激素血症、中心型肥胖和糖脂代谢紊乱,非肥胖型PCOS主要表现为黄体生成激素(luteinizing hormone,LH)水平异常升高。尽管肥胖型和非肥胖型PCOS均存在内分泌代谢异常,然而肥胖可加重PCOS糖脂代谢紊乱;肥胖型PCOS还表现脂肪代谢的异常。综述肥胖型PCOS患者的临床特征、性激素水平、糖脂代谢特征,旨在为肥胖型和非肥胖型PCOS患者新的分型诊治提供参考。 相似文献
20.